黑色素瘤病灶的遗传布局与BRAF/MEK靶向治疗耐药及转录谱相关
本研究通过靶向二代测序和全外显子测序,分析接受维莫非尼或达拉非尼联合曲美替尼治疗中出现完全/持久缓解或疾病进展的转移性黑色素瘤患者的肿瘤样本,定义了101个失衡基因,发现耐药肿瘤和细胞系的突变模式富集于致癌信号通路和DNA修复基因家族,且突变富集与转录水平上相应基因特征的显著正向调节相关,MTORC1信号在反应差的患者肿瘤及耐药肿瘤中富集。
要点
- 耐药黑色素瘤和细胞系的突变模式富集于致癌信号通路和DNA修复基因家族。
- 合成代谢过程、染色质改变和IFN-α反应相关基因集的突变富集导致转录水平上相同基因特征的显著正向调节。
- MTORC1信号在反应差的患者肿瘤及接受治疗患者的耐药肿瘤中富集。
核心结论
- 遗传模式与黑色素瘤靶向治疗耐药相关,并揭示了用于定义药物组合以改进个性化治疗的关键分子通路。
研究设计与样本
- 通过靶向二代测序和全外显子测序分析接受维莫非尼或达拉非尼联合曲美替尼治疗的转移性黑色素瘤患者的肿瘤样本,比较完全/持久缓解与疾病进展患者的基因改变,并整合转录谱特征。
主要发现
- 定义了101个在完全/持久缓解或疾病进展患者转移性肿瘤中失衡的基因。
- 耐药肿瘤和黑色素瘤细胞系的突变模式富集于致癌信号通路和DNA修复基因家族。
- 合成代谢过程、染色质改变和IFN-α反应相关基因集的突变富集导致转录水平上相同基因特征的显著正向调节。
- MTORC1信号在反应差的患者肿瘤及接受治疗患者的耐药肿瘤中富集。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The genetic landscape of melanoma resistance to targeted therapy with small molecules inhibiting BRAF and MEK kinases is still largely undefined. In this study, we portrayed in detail the somatic alterations of resistant melanoma and explored the associated biological processes and their integration with transcriptional profiles. By targeted next-generation sequencing and whole-exome sequencing analyses, a list of 101 genes showing imbalance in metastatic tumors from patients with a complete/durable response or disease progression during therapy with vemurafenib or with dabrafenib and trametinib was defined. Classification of altered genes in functional categories indicated that the mutational pattern of both resistant tumors and melanoma cell lines was enriched in gene families involved in oncogenic signaling pathways and in DNA repair. Integration of genomic and transcriptomic features showed that the enrichment of mutations in gene sets associated with anabolic processes, chromatin alterations, and IFN-α response determined a significant positive modulation of the same gene signatures at the transcriptional level. In particular, MTORC1 signaling was enriched in tumors from poorly responsive patients and in resistant tumors excised from treated patients. Results indicate that genetic patterns are associated with melanoma resistance to targeted therapy and disclose the underlying key molecular pathways to define drug combinations for improved personalized therapies.
引用
- Vergani E, Busico A, Dugo M, et al. Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. J Invest Dermatol. 2022. PMID: 35643181. doi:10.1016/j.jid.2022.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。